The BET family in immunity and disease

N Wang, R Wu, D Tang, R Kang - Signal transduction and targeted …, 2021 - nature.com
Innate immunity serves as the rapid and first-line defense against invading pathogens, and
this process can be regulated at various levels, including epigenetic mechanisms. The …

Interleukin-36 cytokines in infectious and non-infectious lung diseases

HF Peñaloza, R van der Geest, JA Ybe… - Frontiers in …, 2021 - frontiersin.org
The IL-36 family of cytokines were identified in the early 2000's as a new subfamily of the IL-
1 cytokine family, and since then, the role of IL-36 cytokines during various inflammatory …

Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators

T Rehman, PH Karp, P Tan, BJ Goodell… - The Journal of …, 2021 - Am Soc Clin Investig
Without cystic fibrosis transmembrane conductance regulator–mediated (CFTR-mediated)
HCO3–secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an …

[PDF][PDF] Transcriptional inhibition of host viral entry proteins as a therapeutic strategy for SARS-CoV-2

X Wang, R Dhindsa, G Povysil, A Zoghbi… - …, 2020 - pdfs.semanticscholar.org
There is an urgent need to identify effective therapies for COVID-19 given that a broadly
available and effective vaccine is likely at least one year away. Here, we identify compounds …

RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease

R Jahagirdar, S Attwell, S Marusic, A Bendele… - Molecular …, 2017 - ASPET
Bromodomain (BD) and extra-terminal domain containing proteins (BET) are chromatin
adapters that bind acetylated histone marks via two tandem BDs, BD1 and BD2, to regulate …

RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

D Lamb, D De Sousa, K Quast, K Fundel-Clemens… - Respiratory …, 2021 - Springer
Background RORγt is a transcription factor that enables elaboration of Th17-associated
cytokines (including IL-17 and IL-22) and is proposed as a pharmacological target for severe …

Mucosal immunity in cystic fibrosis

CM Bojanowski, S Lu, JK Kolls - The Journal of Immunology, 2021 - journals.aai.org
The highly complex and variable genotype–phenotype relationships observed in cystic
fibrosis (CF) have been an area of growing interest since the discovery of the CF …

ILC2 lung-homing in cystic fibrosis patients: functional involvement of CCR6 and impact on respiratory failure

A Schulz-Kuhnt, V Greif, K Hildner, L Knipfer… - Frontiers in …, 2020 - frontiersin.org
Cystic fibrosis patients suffer from a progressive, often fatal lung disease, which is based on
a complex interplay between chronic infections, locally accumulating immune cells and …

The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner

DA Erkes, CO Field, C Capparelli… - Pigment cell & …, 2019 - Wiley Online Library
Epigenetic agents such as bromodomain and extra‐terminal region inhibitors (BETi) slow
tumor growth via tumor intrinsic alterations; however, their effects on antitumor immunity …

[PDF][PDF] Cystic fibrosis lung transplant recipients have suppressed airway interferon responses during Pseudomonas infection

DT Dugger, M Fung, L Zlock, S Caldera, L Sharp… - Cell Reports …, 2020 - cell.com
Lung transplantation can be lifesaving in end-stage cystic fibrosis (CF), but long-term
survival is limited by chronic lung allograft dysfunction (CLAD). Persistent upper airway …